Edition:
United States

Vexim SA (ALVXM.PA)

ALVXM.PA on Paris Stock Exchange

9.65EUR
23 Jan 2017
Change (% chg)

-- (--)
Prev Close
€9.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
6,809
52-wk High
€10.45
52-wk Low
€6.99

ALVXM.PA

Chart for ALVXM.PA

About

Vexim SA is a France-based company engaged in the medical sector. The Company develops invasive medical instruments used in preventing and treating vertebral fractures. The Company markets its flagship product, SpineJack, in Germany, the United Kingdom, Austria and Ireland under a agreement with Stryker Corp, in France via its... (more)

Overall

Beta: 0.18
Market Cap(Mil.): €75.50
Shares Outstanding(Mil.): 7.62
Dividend: --
Yield (%): --

Financials

  ALVXM.PA Industry Sector
P/E (TTM): -- 33.72 30.38
EPS (TTM): -0.45 -- --
ROI: -21.98 13.18 14.86
ROE: -22.65 16.79 16.28

BRIEF-Vexim 9M sales rises to 13.3 million euros

* Vexim: +37% sales increase to 13.3 million euros ($14.90 million) as of september 30, 2016 (9 Months) Source text: http://bit.ly/2dZfG5L Further company coverage: ($1 = 0.8928 euros) (Gdynia Newsroom)

Oct 13 2016

BRIEF-Vexim H1 net loss narrows to 2.5 million euros

* H1 net loss EUR 2.5 million ($2.79 million)versus loss of EUR 3.6 million year ago

Sep 20 2016

BRIEF-Vexim signs an agreement with Creatori Health

* Vexim signs a distribution agreement with Creatori Health and expands its market to South Africa Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 13 2016

BRIEF-Vexim registers SpineJack and Masterflow for the treatment of vertebral fractures in Australia

* Vexim announces the registration of its products SpineJack and Masterflow for the treatment of vertebral fractures in Australia Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Sep 06 2016

Earnings vs. Estimates